“Due to the minimally invasive nature of the procedures being studied I expect my patients to be on their feet shortly after the surgery. All our patients to date have gone home on the day of surgery.”
Los Angeles, California (PRWEB) July 20, 2010
Dr. George Rappard, NeuroInterventional Surgeon, has completed treatment on the first 3 patients enrolled in a new spine research study at the Los Angeles Brain and Spine Institute. The goal is to evaluate the safety and effectiveness of the Superion ™ device for treatment of moderate lumbar spinal stenosis as compared to the X-STOP® IPD® device, a commercially available implant requiring an open surgical implantation. The Los Angeles Brain and Spine Institute is one of three sites in California participating in the clinical trial.
Spinal stenosis, a degenerative narrowing of the spaces in the spine that can lead to spinal cord and/or nerve root compression, is believed to be the cause of leg and back pain for nearly 1.2 million Americans. When non-surgical treatments fail to provide relief, patients are traditionally offered a spinal decompression or even fusion surgery. This may require a large incision to remove bone and ligaments pressing on the nerve roots. In contrast, both procedures being studied in the clinical trial are minimally invasive with most patients able to return home the same day.
To qualify for the study, patients must be 45 years or older, have leg symptoms caused by spinal stenosis, had symptoms for at least 6 months, and experience relief when sitting or bending forward. Patients who meet the study criteria and agree to participate in the study will be randomly chosen (like the flip of a coin) to receive either the Superion™ ISS or the X-STOP® IPD® device.
“The Superion and X-stop devices represent a significant advancement in the evolution of minimally invasive spine surgery,” according to Dr. Rappard. “This trial allows me to offer cutting edge therapy to patients suffering from spinal stenosis. Due to the minimally invasive nature of the procedures being studied I expect my patients to be on their feet shortly after the surgery. All our patients to date have gone home on the day of surgery.”
Earl R. Fender, President and Chief Executive Officer for VertiFlex, the manufacturer of the Superion device and clinical study sponsor stated, “We are very pleased to have Dr. Rappard join the Superion U.S Clinical Trial as one of its principal investigators. We expect that the Superion Interspinous Spacer will offer a unique alternative for treating an aging population suffering from spinal stenosis. VertiFlex looks forward to demonstrating beneficial patient outcomes in the clinical research study so that Superion interspinous spacer device may soon be offered to the general public.”
The Los Angeles Brain and Spine Institute provides state of the art comprehensive and minimally invasive brain and spine therapies, including supportive care and cutting edge research. The Institute consists of a seasoned and experienced multi-disciplinary team of neurosurgeons, neurointerventional surgeons, neurocritical care specialists and therapists. Our care is delivered in a compassionate and accessible community based setting.
For more information:
To learn more about minimally invasive and comprehensive spine therapies, visit the Los Angeles Brain and Spine Institute at http://www.LABrainandSpine.com, or email us at info(at)LABrainandSpine(dot)com. On twitter, http://www.twitter.com/LASpine.
Media contact: The Los Angeles Brain and Spine Institute. 818-949-4900.
# # #